Centiva Capital’s Lexaria Bioscience LEXX Stock Holding History

Centiva Capital’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,059	Closed	-$32.8K	–	1821
2023 Q1	$32.8K	Sell	12,059 -1,000	-8%	-$2.85K	﹤0.01%	1402
2022 Q4	$32K	Sell	13,059 -200	-2%	-$479	﹤0.01%	1264
2022 Q3	$32K	Sell	13,259 -900	-6%	-$2.56K	﹤0.01%	1357
2022 Q2	$42K	Buy	+14,159	New	+$37.9K	﹤0.01%	1477

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Centiva Capital's LEXX Position: Q2 2023 in Review

Centiva Capital sold out of Lexaria Bioscience (LEXX) in Q2 2023, closing a stake of 12,059 shares — an estimated $32.8K sold.

Centiva Capital first reported a position in LEXX in Q2 2022 and held it in 4 quarters. The position peaked at $42K in Q2 2022. 14 funds tracked by Wall St. Rank hold LEXX as of Q2 2023.

Centiva Capital reported no remaining Lexaria Bioscience position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 12,059 Lexaria Bioscience shares in Q2 2023, an estimated $32.8K.
Centiva Capital first reported a position in Lexaria Bioscience in Q2 2022 and held it in 4 quarters.
Centiva Capital's Lexaria Bioscience position peaked at $42K in Q2 2022.
14 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.